Moreover, the “one therapy mode suits all” approach in targeting the TNFα-TNFR pathway in cancer needs to be re-evaluated, and emphasis should be given to extensive research that will identify the most appropriate therapeutic mode for each malignancy type/subtype, in a specific and personalized manner. Here, TNFRSF1A is linked to cancer.